Degradable cationic polyglyoxamides and polyglyoxylates for biodegradable polymer solutions
This research explores degradable cationic polyglyoxamides and polyglyoxylates, offering biodegradable polymer solutions with customizable molar masses and cationic side chains. These polymers are suitable for applications requiring environmentally friendly materials.
Overview
This innovative research focuses on the development of degradable cationic polyglyoxamides and polyglyoxylates. Utilizing polymers with acetal backbones, these materials are inherently biodegradable. By modifying these polymers with cationic groups, such as (2-aminoethyl)trimethylammonium salts, a new class of biodegradable polycations is being developed. The polymers are synthesized from ethyl glyoxylate, allowing for control over the molar mass and enabling the creation of block copolymers with other polymers, such as poly(ethylene oxide). This solution aims to provide environmentally friendly alternatives for industries seeking sustainable materials.
Technical specifications
- Degradable backbones: Utilizes ethyl glyoxylate polymers which are inherently biodegradable.
- Cationic side chains: Modification with cationic groups enhances functionality for various applications.
- Customizable molar masses: Control over polymerization allows for a range of molar masses.
- Block copolymers: Potential to create block copolymers with other functional polymers like poly(ethylene oxide).
- Research basis: Builds on established research showing controlled polymerization and applicability in forming soft hydrogels.
Technology readiness level
The current technology readiness level is 2, indicating that the concept is formulated and initial experimental proof of concept has been demonstrated. Future validation involves molecular characterization, iterative redesign, and moderate scale-up in collaboration with industrial partners.
About Stony Brook University
Stony Brook University is a comprehensive public research university on Long Island and New York’s flagship, recognized as a Carnegie R1 institution and a member of the Association of American Universities. Companies connect through a research and development park with co-located incubators and growth programs, alongside convenient access to New York City and Long Island industry. Health system integration through Stony Brook Medicine enables clinical collaboration and translation, while a co-management role at nearby Brookhaven National Laboratory opens pathways to DOE user facilities and joint initiatives. Research is supported by competitive federal funding from agencies such as NIH, NSF, and DOE. A dedicated technology transfer office, Intellectual Property Partners, streamlines IP, licensing, and industry agreements, including flexible CLEAR‑IP options.
delivered to your inbox.